A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model

Consumption of a western diet and high body mass index (BMI) are risk factors for progression from pre-malignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible, improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease-progression trajectory improved (n=2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma-precursor state, in which a high-fiber diet delayed disease progression through improved metabolism and microbiome composition leading to increased short-chain fatty acid production that reinvigorated anti-tumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A high-fiber diet is a low-risk intervention that may delay progression to myeloma.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2025-12-04
DOI
https://doi.org/10.1158/2159-8290.cd-25-1101
Citations
5
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
8.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model

Susan Chimonas, Rúben J. Ramos, Neil M. Iyengar, Heather Jolie Landau et al.
5 citations
Cancer Discovery
Multiple Myeloma Research and Treatments
8.85
article

A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model

Susan Chimonas, Rúben J. Ramos, Neil M. Iyengar, Heather Jolie Landau, Marcel R.M. van den Brink, P. Leif Bergsagel, Kylee H. Maclachlan, Michaël Pollak, Marta Chesi, Justin R. Cross, Nicola Clementi, Saad Z. Usmani, Oscar Boutros Lahoud, Kinga Hosszu, Jenna Blaslov, Malin L. Hultcrantz, Brianna Gipson, Matteo Bellone, Gunjan L. Shah, Urvi Ashok Shah, Susan DeWolf, Alexander M. Lesokhin, Juan‐José Garcés, Jonathan U. Peled, Anita D’Souza, Sofia Sisti, Nathan Aleynick, Michael Scordo, Torin Block, Leonardo Boiocchi, Erica Salehi, Paola Zordan, Peter A. Adintori, Sara Pagani, Devin McAvoy, David J. Chung, Aishwarya Anuraj, Hani Hassoun, Sandeep S. Raj, Sham Mailankody, Neha Korde, Marco Lorenzoni, Ana Gradíssimo, Richard P. Koche, Francesca Castro, Sergio A. Giralt, Matteo Grioni, Andriy Derkach, Ola Landgren, Ronan Chaligné, J Paredes, Laura Lucia Cogrossi, Charlotte Pohl, Carlyn Rose C. Tan, Anna Policastro, Mirae Baichoo, Teng Fei, Victoria Zinsmeyer, Camilla Marchigiani
article en
5 citations

Abstract

Consumption of a western diet and high body mass index (BMI) are risk factors for progression from pre-malignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible, improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease-progression trajectory improved (n=2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma-precursor state, in which a high-fiber diet delayed disease progression through improved metabolism and microbiome composition leading to increased short-chain fatty acid production that reinvigorated anti-tumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A high-fiber diet is a low-risk intervention that may delay progression to myeloma.

Cancer Discovery
City Of Hope National Medical Center (US), Northwell Health (US), Memorial Sloan Kettering Cancer Center (US), Vita-Salute San Raffaele University (IT), Medical College of Wisconsin (US), Cornell University (US), San Raffaele University of Rome (IT), Kettering University (US), NYU Langone Health (US), City of Hope (US), Mayo Clinic in Arizona (US), IRCCS Ospedale San Raffaele (IT), NutritionQuest (United States) (US), Sylvester Comprehensive Cancer Center (US), McGill University (CA), New York University (US)
Openalex Percentile: Top 2%
Multiple Myeloma Research and Treatments
8.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.